{
    "body": "Mutations in which gene determine response to both erlotinib and gefitinib?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21430269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22263058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22738915", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23332287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18799900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19063875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21777765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19808904", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17575237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17145836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18997733", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20647703", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20705455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15737014", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16199108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16730855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16009451", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22806307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23507588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16049312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22920167", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20948254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20512075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18726117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20007486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21904575", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16705038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15329413"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7647895", 
            "o": "Gene Mutation"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0596611", 
            "o": "http://linkedlifedata.com/resource/umls/label/A7850263"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7850263", 
            "o": "Gene Mutation"
        }
    ], 
    "ideal_answer": [
        "Patients who carry somatic activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene, respond well to erlotinib and gefitinib."
    ], 
    "exact_answer": [
        "epidermal growth factor receptor (EGFR) gene"
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#4274201", 
        "http://www.biosemantics.org/jochem#4241662", 
        "http://www.biosemantics.org/jochem#4241661"
    ], 
    "type": "factoid", 
    "id": "51542e44d24251bc05000081", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 124, 
            "text": "Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in non-small-cell lung cancer (NSCLC),", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332287", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 223, 
            "offsetInEndSection": 445, 
            "text": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332287", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 53, 
            "offsetInEndSection": 361, 
            "text": "Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib,", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22738915", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 341, 
            "text": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer (NSCLC). Patients with somatic activating mutations in the EGFR gene have dramatic response initially, but would eventually develop resistance to these TKIs.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22263058", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 242, 
            "offsetInEndSection": 546, 
            "text": "NSCLCs with EGFR mutations (exon 19 deletions or the exon 21 L858R) attain responses to EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, with improved response rate (RR), progression-free survival (PFS) and in some reports overall survival (OS) when compared with EGFR wildtype (WT) cases.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21904575", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 216, 
            "text": "Patients presenting with non-small cell lung cancer (NSCLC) and active EGFR mutation have a high response rate (60-70%) to EGFR tyrosine kinase inhibitors (TKI) with little immediate progression (primary resistance).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21777765", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 163, 
            "text": "Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21430269", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 141, 
            "text": "EGFR-TKI yields a long survival period in cases of non-small cell lung cancer (NSCLC), especially those with EGFR gene mutations,", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948254", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 582, 
            "offsetInEndSection": 706, 
            "text": "Efficacy of erlotinib was recognized in the cases in which disease control was obtained by initial treatment with gefitinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948254", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 205, 
            "text": "Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20705455", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 24, 
            "offsetInEndSection": 188, 
            "text": "lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib;", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20007486", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 204, 
            "text": "The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808904", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 425, 
            "offsetInEndSection": 823, 
            "text": "Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808904", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 229, 
            "text": "Patients with advanced pulmonary adenocarcinoma exhibiting overexpression or mutation of epidermal growth factor receptor tend to respond better to targeted therapy with tyrosine kinase inhibitors such as gefitinib and erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18997733", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 496, 
            "text": "Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-small-cell lung cancer (NSCLC), especially in patients with adenocarcinoma and never smokers. Some common somatic mutations in EGFR, including deletion mutations in exon 19 and leucine-to-arginine substitution at amino acid position 858 (L858R) in exon 21, have been examined for their ability to predict sensitivity to gefitinib or erlotinib, which are selective EGFR tyrosine kinase inhibitors (EGFR-TKIs).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730855", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 249, 
            "text": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16705038", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 196, 
            "text": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16049312", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 325, 
            "offsetInEndSection": 523, 
            "text": "Epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)(such as gefitinib or erlotinib)treatment of lung cancer harboring EGFR gene mutation is one of the prototypes of such therapies.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23507588", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 380, 
            "offsetInEndSection": 630, 
            "text": "patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806307", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 491, 
            "offsetInEndSection": 707, 
            "text": "The evidence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) such as gefitinib and erlotinib was first confirmed as the second-line treatment for non-selective patients with advanced NSCLC.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647703", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 927, 
            "offsetInEndSection": 1402, 
            "text": "patients with EGFR-mutated advanced NSCLC, the first-line treatment with gefitinib had achieved a significant prolongation of progression-free survival compared with standard platinum doublet chemotherapy in a few phase III trials, and became a new standard of care. Gefitinib is highly effective for patients with advanced NSCLC with EGFR mutation even if their performance status is poor, although one should always pay careful attention to fatal interstitial lung disease.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647703", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 187, 
            "text": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512075", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 226, 
            "text": "Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the responses to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with non-small-cell lung cancer (NSCLC).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19063875", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1051, 
            "offsetInEndSection": 1393, 
            "text": "EGFR tyrosine kinase inhibitors (gefitinib, erlotinib), which are molecularly targeted drugs, and it has now become possible to select treatment methods by choosing from a number of anticancer drugs. EGFR tyrosine kinase inhibitors have been demonstrated to have a very high cytoreductive effect on lung cancers that have EGFR gene mutations.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799900", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 224, 
            "offsetInEndSection": 385, 
            "text": "EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726117", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 214, 
            "offsetInEndSection": 386, 
            "text": "responsive patients can relapse as a result of selection for EGFR gene mutations that confer resistance to ATP competitive EGFR inhibitors, such as erlotinib and gefitinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575237", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 28, 
            "offsetInEndSection": 254, 
            "text": "the epidermal growth factor receptor (EGFR) was a therapeutic target in non-small cell lung cancer (NSCLC) and other cancers led to development of the small-molecule receptor tyrosine kinase inhibitors gefitinib and erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145836", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1387, 
            "offsetInEndSection": 1501, 
            "text": "There was a significant correlation between EGFR gene copy number, EGFR gene mutations, and gefitinib sensitivity.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145836", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 170, 
            "text": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199108", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 262, 
            "text": "Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16009451", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 204, 
            "text": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329413", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1567, 
            "offsetInEndSection": 1689, 
            "text": "frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329413", 
            "endSection": "sections.0"
        }
    ]
}